A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT06136741. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-human interleukin-2 (rezpegaldesleukin) in adult participants with moderate to severe atopic dermatitis. The estimated duration is 15-35 days for screening, an Induction Period of 16 weeks, a Maintenance Period from Week 16-Week 52, and a Posttreatment Follow-Up Period for an additional year up to approximately Week 104 for all patients. Patients with a response at Week 16 (end of induction therapy) will be re-randomized for the maintenance therapy period.
Study identification
- NCT ID
- NCT06136741
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 396 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 15, 2023 (Actual)
- Primary completion
- May 6, 2025 (Actual)
- Completion
- Dec 31, 2026 (Estimated)
- Last update posted
- Aug 21, 2026
2023 – 2026
United States locations
- U.S. sites
- 28
- U.S. states
- 13
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Nektar Investigative Site | Bryant | Arkansas | 72022 | — |
| Nektar Investigative Site | Fountain Valley | California | 92708 | — |
| Nektar Investigative Site | Los Angeles | California | 90017 | — |
| Nektar Investigative Site | Los Angeles | California | 90025 | — |
| Nektar Investigative Site | Los Angeles | California | 90057 | — |
| Nektar Investigative Site | Santa Monica | California | 90404 | — |
| Nektar Investigative Site | Hialeah | Florida | 33016 | — |
| Nektar Investigative Site | Hollywood | Florida | 33021 | — |
| Nektar Investigative Site | Miami | Florida | 33173 | — |
| Nektar Investigative Site | Miami Lakes | Florida | 33014 | — |
| Nektar Investigative Site | St. Petersburg | Florida | 33705 | — |
| Nektar Investigative Site | Tampa | Florida | 33615 | — |
| Nektar Investigative Site | Marietta | Georgia | 30060 | — |
| Nektar Investigative Site | Clarksville | Indiana | 47129 | — |
| Nektar Investigative Site | Indianapolis | Indiana | 46202 | — |
| Nektar Investigative Site | Louisville | Kentucky | 40241 | — |
| Nektar Investigative Site | Flint | Michigan | 48532 | — |
| Nektar Investigative Site | Troy | Michigan | 48084 | — |
| Nektar Investigative Site | Las Vegas | Nevada | 89106 | — |
| Nektar Investigative Site | New York | New York | 10075 | — |
| Nektar Investigative Site | Fairborn | Ohio | 45324 | — |
| Nektar Investigative Site | Mayfield Heights | Ohio | 44124 | — |
| Nektar Investigative Site | Murfreesboro | Tennessee | 37130 | — |
| Nektar Investigative Site | Bellaire | Texas | 77401 | — |
| Nektar Investigative Site | Cypress | Texas | 77429 | — |
| Nektar Investigative Site | Frisco | Texas | 75034 | — |
| Nektar Investigative Site | Spokane | Washington | 99202-1461 | — |
| Nektar Investigative Site | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 79 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06136741, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06136741 live on ClinicalTrials.gov.